Evidence is emerging that the closely related ROCK1 and ROCK2 serine/threonine kinases support the invasive and metastatic growth of a spectrum of human cancer types. Therefore, inhibitors of ROCK are under preclinical development.
Introduction
There is considerable and growing evidence for the importance of the ROCK serine/threonine kinases (ROCK1/ROKβ and ROCK2/ROKα) kinases in oncogenesis (1, 2) . The highly related ROCK1 and ROCK2 kinases function as key downstream effectors of the RhoA small GTPase (3) . ROCK regulates diverse cellular processes such as actomyosin contractility, focal adhesion assembly, cytokinesis, and cell proliferation. ROCK has also been implicated in colorectal, breast, gastric, and glioblastoma proliferation or anchorage-independent growth (4-7) and in prostate, bladder, fibrosarcoma, melanoma, and hepatocellular cancer metastatic growth (8) (9) (10) (11) (12) (13) ).
An evaluation of ROCK as a therapeutic target for lung cancer has not been done.
Although preclinical development of ROCK inhibitors is ongoing, a number of issues need to be resolved to facilitate their clinical development. First, genetic or biochemical determinants that identify cancers responsive to ROCK inhibitors need to be identified. Second, biomarkers that correlate with inhibitor anti-tumor response are needed for effective clinical evaluation. Although the phosphorylation status of key substrates of ROCK is widely utilized, their value as biomarkers for ROCK inhibition remains unresolved. Third, the majority of studies implicating ROCK in cancer growth utilized the Y-27632 ROCK inhibitor (1, 2) . Since Y-27632 can inhibit other protein kinases in vitro, whether the anti-tumor activities ascribed to this inhibitor are targetbased is unresolved.
One candidate molecular determinant for ROCK inhibitor sensitivity is the loss of expression of the DLC1 tumor suppressor (14) . DLC1 mRNA expression was lost in 95% of NSCLC patient tumors and 58% of NSCLC cell lines (15, 16) . Due at least in part through its function as a Rho GTPase activating protein and thus negative regulator Author Manuscript Published OnlineFirst on August 31, 2012; DOI: 10.1158/0008-5472. CAN-11-2373 of RhoA and the related RhoB and RhoC, restoration of DLC-1 expression in DLC1 deficient NSCLC lines resulted in reduction of cell migration, proliferation, anchorageindependent growth, in vitro invasion, and tumorigenicity in nude mice (16) (17) (18) , supporting its role as a tumor suppressor (19) . It is well-established that aberrant RhoA and RhoC activation can promote tumorigenic, invasive and metastatic growth (20) (21) (22) .
Thus, by analogy to the loss of the neurofibromin RasGAP or the tuberous sclerosis RhebGAP in cancer (23, 24) , loss of DLC-1 results in hyperactivation and persistent RhoA/C effector signaling (15, 25) . However, like Ras, Rho GTPases are not tractable molecules for drug discovery (14) . Instead, in further analogy to Ras, where inhibitors of the Raf-MEK-ERK effector protein kinase pathway are being considered for anti-Ras drug development (26) , inhibitors of RhoA/C downstream effector protein kinases, in particular ROCK, may also be attractive therapeutic targets for DLC1-deficient NSCLC.
In support of this possibility, ectopic expression of DLC-1 suppressed ROCK activation and ROCK-dependent motility in DLC-1 deficient hepatocellular carcinoma cell lines (27) ., and suppression of DLC-1 expression sensitized liver cancer cells to reduced colony formation by pharmacologic inhibition of ROCK (19) .
In light of the frequent loss of DLC1 expression in NSCLC, we speculated that DLC1 loss-induced activation of RhoA/C will in turn cause ROCK activation-driven NSCLC tumorigenic and malignant growth. However, previous studies implicating ROCK in cancer growth have relied primarily on the use of Y-27632 ATP competitive ROCK1/2 kinase inhibitor, which has additional off-target inhibitory activity for other kinases such as PKN and MSK1 (28) . To offset this concern, we utilized a structurally distinct and more potent and selective small molecule ROCK1/2 inhibitor together with RNA interference depletion of ROCK1/2 expression to validate a role for ROCK in DLC1 6 deficient NSCLC growth. We determined that NSCLC anchorage-dependent growth was ROCK-independent, but anchorage-independent growth and Matrigel invasion were ROCK-dependent. However, loss of DLC-1 expression did not correlate with ROCK dependence. ROCK inhibition of growth was associated with inhibition of cell cycle progression rather than enhancement of cell death. Our studies provide validation of ROCK for NSCLC therapy.
Materials and Methods
Identification and characterization of the OXA-06 ROCK inhibitor ROCK1/2 cDNA sequences were subcloned into a baculovirus expression vector for protein expression as a C-terminal fusion protein with His 6 in insect cells. The expressed protein (comprising residues 2-238 of ROCK1 fused to residues 255-548 of ROCK2) was purified and used in a fluorescence polarization assay-based highthroughput screening campaign to identify ROCK kinase inhibitors within OSI Pharmaceuticals compound library. The screening assay buffer consisted of 10 mM Tris HCl (pH 7.2), 10 mM MgCl2, 0.1% BSA, 1 mM DTT and contained 100 nM substrate peptide (5'-FAM-AKRRRLSSLRA-COOH), 1 μM ATP and 12.5 nM ROCK kinase domain. A series of azaindole-based compounds was selected for medicinal chemistry optimization, and synthetic routes for this series are described within patent application 
Protein kinase selectivity assays
Kinase selectivity assays were performed using ProfilerPro Kinase Selectivity Kits (Caliper Life Sciences, Inc.) according to the manufacturer's instructions. The extent of inhibition by each compound is measured directly by quantifying the level of both unphosphorylated and phosphorylated peptide substrate after electrophoretic separation. Assays were performed at room temperature following a one h preincubation of compounds with the enzymes. Each assay was performed on two separate occasions.
Quantitative assays of MYPT1 phosphorylation and cell migration in PANC-1 cells
Analysis of MYPT1 phosphorylation in PANC-1 cells by quantitative ELISA was performed as described previously (29) . PANC-1 cell migration was quantitated using 96-well modified Boyden chamber migration assay plates (Chemicon, Temecula, CA).
Cells were applied to the upper chamber in growth medium supplemented with 0.5% fetal calf serum (FCS), either in the presence or absence of inhibitor, and the cells were 
Statistical analysis
Data were analyzed using an unpaired t test. Values are shown as means ± S.D.
A P value <0.01 was considered significant. Forty-eight h after transfection, transfected cells were harvested for either analyses of anchorage-independent growth or for western blot analyses. Data were analyzed using a paired t test. Values are shown as means ± S.D. A P value <0.01 was considered highly significant.
Western blot analyses

Results
OXA-06 is a novel and potent ROCK inhibitor
In light of the off-target activities of the Y-27632 ROCK inhibitor, we initiated a highthroughput screening of the OSI Pharmaceuticals compound library using recombinant CAN-11-2373 were noted between the two compounds. OXA-06 showed >50% inhibition of 9 out of 167 (5.4%) whereas Y-27632 inhibited 17 out of 167 (10.2%) (Fig. 1B) . Both shared activity for five additional protein kinases, whereas OXA-06 was active on two other kinases and Y-27632 was active on 10 additional kinases. These results demonstrate the greater selectivity of OXA-06 over Y-27632. Additionally, this degree of selectivity is comparable or better than highly selective protein kinase inhibitors (e.g., imatinib, gefitinib) currently in clinical use (32, 33) . We conclude that the different and improved kinase inhibition selectivity profile, together with being structurally distinct from Y-27632, support the usefulness of OXA-06 to investigate the role of ROCK kinase activity in cellular processes.
We next determined if OXA-06 could block ROCK activity in intact cells. We determined previously that siRNA suppression of ROCK1 and ROCK2 expression, and additionally treatment with three different ROCK1/2 inhibitors, reduced the phosphorylation of MYPT1 at T853 was ROCK-dependent in PANC-1 pancreatic tumor cells (29) . PANC-1 migration was also shown previously to be ROCK-dependent (34) .
We determined that OXA-06 treatment of PANC-1 cells showed dose-dependent inhibition of MYPT1 phosphorylation (IC 50 300 nM) and migration in vitro ( Supplementary Fig. 1 ). By comparison Y-23732 showed a reduced potency to inhibit MYPT1 phosphorylation (IC 50 1.4 μM) and migration.
OXA-06 blocks anchorage-independent growth and invasion of NSCLC lines
We next utilized OXA-06 to validate the importance of ROCK1/2 as therapeutic targets. Western blot analyses of 16 NSCLC cell lines determined that all lines express ROCK1 and ROCK2 protein ( Fig. 2A) . Based on previous studies with other cancer types (19, 27) , we hypothesized that the absence of DLC-1 expression might be a predictor of sensitivity to inhibition of ROCK1 and/or ROCK2. For these analyses, we evaluated the A549, H23 and H358 cell lines which lack DLC-1 protein expression, and the H1299 and H1703 cell lines that express high levels of DLC-1 (18) . Surprisingly, none of the cell lines was inhibited in anchorage-dependent proliferation by treatment with 2 or 10 μM OXA-06 (Fig. 2B) . However, at the highest concentration of OXA-06 used, 10 µM, greater than 90% anchorage-independent growth inhibition was achieved in all the lines tested (Fig. 2C) . While 400 nM was sufficient to cause ~90% reduction in the colony formation activity of the DLC-1 positive H1299 cell line, this concentration did not cause statistically significant inhibition of the DLC-1 negative A549 and H358 or the DLC-1 positive H1703 cell lines.
Since OXA-06 also inhibited seven other kinases in vitro (e.g., PKA), we also assessed the ability of Y-27632 to inhibit anchorage-independent growth of H1299 and A549 cells. In both lines, Y-27632 also caused a decrease in anchorage-independent growth, suggesting a ROCK-dependent for anchorage-independent growth, although Y-27632 had much weaker potency than OXA-06 (Fig. 3) . This increased potency of OXA-06 compared to Y-27632 in blocking anchorage-independent growth is consistent with its increased potency in vitro and in ROCK-dependent cell-based assays (Fig. 1B, Supplementary Table 1 and Supplementary Fig. 1 ). Similar to their sensitivity to inhibition of anchorage-independent growth by OXA-06, both DLC-1 negative and positive NSCLC cell lines showed comparable dose-dependent sensitivities to OXA-06 suppression of Matrigel invasion, with ~70% inhibition seen at 2 μM (Fig. 2D) . The observation that Matrigel invasion and anchorage-independent growth were inhibited at similar concentrations of OXA-06 is consistent with the inhibitor blocking both tumor phenotypes through inhibition of the same target(s). We conclude that loss of DLC-1 did not correlate with increased sensitivity to OXA-06.
One possible basis for the lack of correlation between DLC-1 loss of expression and increased sensitivity to OXA-06 is that DLC-1 expression alone does not determine the steady-state level of RhoA activation. The activities of RhoGEFs as well as RhoGAPs will also influence RhoA steady-state levels. Consistent with this possibility, we performed pull down analyses to quantitate the steady-state levels of active RhoA-GTP in a panel of NSCLC cell lines. We found no direct correlation between elevated RhoA-GTP levels the absence of DLC-1 protein expression (Fig. 2E) .
OXA-06 anti-tumor activity correlates with suppression of Cofilin phosphorylation
To investigate the mechanism of OXA-06-mediated inhibition of growth and invasion, we determined if the anti-tumor activity of OXA-06 correlated with inhibition of ROCK activity. Two well-characterized ROCK-dependent phosphorylation activities are direct ROCK phosphorylation of the MYPT1 and the indirect phosphorylation of Cofilin through ROCK phosphorylation and activation of LIMK1/2. However, since both MPYT1 and Cofilin can be phosphorylated by ROCK-independent mechanisms, their phosphorylation state may or may not accurately monitor ROCK activity.
We found that OXA-06 treatment reduced pMYPT1 and pCofilin levels at concentrations that coincided with that required to block anchorage-independent growth. These data are consistent with ROCK inactivation as a key mechanism for OXA-06 anti-tumor activity. However, the extent of phosphorylation reduction and the inhibitor concentration required for this effect varied between different cell lines (Fig. 4) . the most sensitive to OXA-06 colony suppression (Fig. 2C ) and pCofilin reduction was seen at the lowest concentrated used, 80 nM. In contrast, H358 cells were the most resistant to OXA-06 colony suppression and even at the highest concentration studied (10 μM), incomplete reduction in pCofilin was seen. For the remaining three NSCLC cell lines, 10 μM was required for near-complete suppression of pCofilin as well as soft agar growth. In contrast, pMYPT1 levels were less informative, largely because two cell lines lacked detectable phosphorylation in untreated cells. For A549, but not H358 cells, this was most likely due to the barely detectable levels of MYPT1 expression.
Where it could be detected, pMYPT1 did show dose-dependent reduction that coincided with OXA-06 concentrations needed for growth inhibition. Thus, Cofilin phosphorylation may provide a useful biomarker for ROCK inhibition in NSCLC.
Genetic suppression of ROCK1 and/or ROCK2 expression phenocopies the biochemical and biological activities of OXA-06
Although ROCK1/2 were the protein kinases most potently inhibited by OXA-06 in vitro (Table 1) , it is possible that the effects of OXA-06 on NSCLC anchorageindependent growth and invasion resulted from inhibition of other kinases. To confirm that ROCK kinase inhibition contributes to the anti-tumor activity of OXA-06, we specifically reduced ROCK1 and ROCK2 expression with siRNA validated previously to be selective inhibitors of ROCK1 and ROCK2 (29) . We utilized two independent siRNA sequences each for ROCK1 and ROCK2 in H1299 cells that caused near complete knockdown of ROCK1 and/or ROCK2 protein expression (Fig. 5A) . Interestingly, neither ROCK1 nor ROCK2 depletion individually was able to strongly reduce pMYPT1 or pCofilin, and instead, concurrent depletion of both was required to reduce pMYPT1 and to a lesser extent pCofilin (Fig. 5A ). This result demonstrates that both ROCK isoforms are functionally redundant for these signaling activities.
In contrast, we found that depletion of either ROCK1 or ROCK2 alone, using two independent siRNA sequences each, was sufficient to potently (~90%) inhibit the anchorage-independent growth of H1299 cells. Concurrent suppression of both ROCK1 and ROCK2 more effectively suppressed growth with a near complete suppression of colony formation (Fig. 5B) . Thus ROCK1 and ROCK2 each contribute non-redundant activities to support anchorage-independent growth. Finally, we determined that, similar to OXA-06 treatment, concurrent depletion of ROCK1 and ROCK2 did not significantly impair anchorage-dependent proliferation (Fig. 5C ). That siRNA for ROCK1 and ROCK2 phenocopied the biological activities of OXA-06 suggests that the anti-tumor activities seen with OXA-06, despite having other protein kinase targets, are likely due primarily to inhibition of ROCK1 and ROCK2.
OXA-06 stimulates accumulation in G 0 /G 1 phase but not apoptosis in nonadherent NSCLC cells
Although we found that prolonged OXA-06 treatment did not reduce NSCLC cell line viability on plastic (Fig. 3B) sensitivity is not a mechanism for the decreased anchorage-independent growth seen with OXA-06.
We next determined if OXA-06 impaired soft agar colony formation by disruption of cell cycle progression under anchorage-independent conditions. We used propidium iodide staining and flow cytometry to investigate possible cell cycle distribution effects of OXA-06 on two NSCLC cell lines treated with inhibitor in suspension. OXA-06 treatment at 1 µM in suspension (a concentration that is around the cellular IC 50 value for reduced anchorage-independent growth, invasion, and downstream ROCK target phosphorylation) caused a statistically significant reduction in S phase and an increase in G 0 /G 1 (Fig. 6A ).
To confirm that ROCK inhibition is required for these effects of OXA-06, we used siRNA to reduce ROCK1 and ROCK2 protein expression and we found that concurrent suppression of ROCK1 and ROCK2 expression also caused a very similar cell cycle phenotype (Fig. 6B) . This result suggests that these activities of OXA-06 on the cell cycle are due to inhibition of ROCK. Furthermore, we did not detect any sub-G 0 peaks in the analysis of OXA-06 at 1 μM (Fig. 6) or at 10 μM (data not shown), or ROCK1/ROCK2 siRNA (Fig. 6) , which when taken together with lack of full caspase-3 or PARP cleavage, excludes anoikis or necrosis as a mechanism for the ROCK inhibition-dependent block in anchorage-independent growth. Finally, we evaluated the effects of OXA-06 treatment on two key regulators of G 1 progression, the Rb tumor suppressor and cyclin D1. Using western blot analysis on OXA-06 treated A549 or H1299 cells in suspension at 2 or 10 μM, we did not observe increased Rb phosphorylation at S608 (a site phosphorylated by cyclin/CDK complexes) nor decreased levels of cyclin D1 (Supplementary Fig. 2B ). We also did analysis for 
consequences on NSCLC growth suggests that the anchorage-independent growth and Matrigel invasion inhibition seen is due to loss of ROCK protein kinase function.
Furthermore, as discussed below, our findings that OXA-06 anti-tumor activity correlated well with OXA-06 inhibition of phosphorylation of known direct and indirect ROCK substrates and that siRNA for ROCK phenocopied the effects of OXA-06 on anchorage-dependent and -independent growth strongly support our conclusion that ROCK kinases represent functionally relevant targets of OXA-06 in NSCLC growth.
Thus, while OXA-06 can inhibit other protein kinases, our siRNA results argue that the anti-tumor activity observed in NSCLC cell lines may be due primarily to ROCK inhibition. The FDA approval of the dasatinib and sunitinib protein inhibitors for cancer treatment, both of which show activity (Kd <100 nM) for greater than 15% of the 290 protein kinases tested (38) , clearly demonstrate that multi-kinase inhibitors can be developed successfully for therapeutic use.
OXA-06 does not have sufficient pharmacokinetic/pharmacodynamic properties for use in animal studies (unpublished observations), but it provides a more potent and selective inhibitor than the widely used Y-27632 compound to study ROCK function in cell culture. More importantly, our results support the discovery and development of potent and selective ROCK inhibitors in animal models of NSCLC.
The second goal of our study was to determine if DLC-1 loss of expression is a reliable biomarker for NSCLC tumor cell ROCK dependency. In contrast to two recent studies that found ROCK important for DLC-1 tumor suppressive effects in hepatocellular carcinoma (19, 27) , we found that DLC-1 expressing and deficient cells were comparably sensitive to OXA-06 and additionally showed comparable levels of phosphorylation of ROCK substrates. This disconnect is not entirely surprising for 
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several reasons. First, there exist a multitude of GEFs and GAPs for RhoA/C (14) .
Thus, the steady-state activation of RhoA-C and ROCK may not be dictated solely by loss of DLC-1 alone. Consistent with this possibility, we found no direct correlation between the level of DLC-1 protein reduction and increased cellular RhoA-GTP levels.
Furthermore, in studies of a DLC-1 mutant that failed to associate with focal adhesions, this disrupted subcellular localization was not associated with a loss in the ability to lower total cellular RhoA-GTP levels (39) . Thus, it is not surprising that total RhoA-GTP levels are not tightly linked to the level of DLC-1 expression. Second, RhoA/C may utilize non-ROCK effectors to promote tumorigenesis (37) . Finally, DLC-1 can also serve as a GAP for other Rho family proteins and DLC-1 tumor suppressor function involves both Rho-dependent and Rho-independent mechanisms (18) . These additional complexities of DLC-1 function may prevent a simple and direct relationship between DLC-1 expression loss and ROCK-dependent growth. Perhaps the combined use of DLC-1 loss together with hyperphosphorylation of ROCK substrates will provide a more reliable marker to predict ROCK dependency.
The third goal of our study was to determine if the widely studied substrates for ROCK activity provided accurate biochemical markers that correlated with OXA-06-mediated growth inhibition. While our studies found that Cofilin, rather than MYPT1, provided a more accurate biomarker for pan-ROCK inhibitor treatment, our use of isoform-specific siRNA to selectively silence ROCK1 or ROCK2 found that inhibition of either isoform alone inhibited anchorage-independent growth, yet inhibition of both While our analyses did not establish a mechanism for why ROCK dependency was not evident for cells grown on plastic, previous studies suggest that loss of integrindependent signaling events (38, 39) are a likely basis for ROCK dependency for cells in suspension. Finally, how tumor cells will respond to ROCK inhibition within the context of host stromal tissue will be an important future question to address using both pharmacologic inhibitors and conditional ROCK knockouts in mouse models of lung cancer.
In summary, our studies provide strong validation of ROCK1 and/or ROCK2 as useful targets for NSCLC therapy. Furthermore, despite the potentially significant offtarget activities of our newly identified OXA-06 ROCK inhibitor, our demonstration that as we determined previously. E, Elevated steady-state RhoA activity levels do not correlate with loss of DLC-1 expression. Pull down analyses, followed by blot analysis for RhoA, was done to measure the level of activated RhoA-GTP and total RhoA expression. β-actin blot analysis was done to verify equivalent total protein loading. 
